Supplementary Figure 4 from Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative Oncology Group E2303

Authors :: Arlene A. Forastiere
Harold J. Wanebo
David L. Rimm
Barbara A. Burtness
Efstratios K. Kosmidis
Maria Vassilakopoulou
Eirini Pectasides
Ju-Whei Lee
Amanda Psyrri
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: PDF file - 55K, Kaplan-Meier estimates of (a) overall survival, (b) progression-free survival by NRAS and ERK cluster status.

Full Text Access

Tools